Sign in
CompletedPhase 2

Ketamine for Methamphetamine Use Disorder

Key facts

Who runs it
University of Texas Southwestern Medical Center
Where
Albuquerque, Dallas, Greenville, New York, and San Leandro, United StatesSee the 5 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
120 people enrolled
Started
11 Sept 2024
Ended
15 Oct 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ketamine Hydrochloride
  • Midazolam Hydrochloride
Record updated
27 October 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Study participants must:
  • Be 18 to 65 years old
  • Be able to sufficiently understand, speak, and read English
  • Be interested in reducing or stopping methamphetamine use
  • Meet criteria for methamphetamine use disorder
  • Use acceptable methods of contraception during participation in the study

Who cannot take part

  • Have been in a research study of pharmacological or behavioral treatment for addiction within 6 months prior to written informed consent
  • Have upcoming surgery planned or scheduled
  • Study participants must not:
  • Be currently in jail, prison, or inpatient overnight facility as required by court of law
  • Be currently pregnant, breastfeeding, or planning on conception, if biologically female; Additional inclusion and exclusion criteria will be assessed by the study investigators at the screening visit

Where in United States

  • Interdisciplinary Substance Use and Brain Injury FacilityAlbuquerque, United States
  • UT Southwestern Medical CenterDallas, United States
  • Prisma HealthGreenville, United States
  • Addiction Institute of Mount SinaiNew York, United States
  • Alameda Health SystemSan Leandro, United States

About the trial

What the trial wants to find out

This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD.

Read full original descriptionShow less

The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).

The 2 groups in the trial

  • KetamineTreatment being tested

    Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV ketamine will be administered 8 times over 6 weeks.

    Treatment: Ketamine Hydrochloride

  • MidazolamExisting treatment, for comparison

    Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV midazolam will be administered 8 times over 6 weeks.

    Treatment: Midazolam Hydrochloride

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
NIDA CTN-0132 Randomized, Double-Blind, Active Placebo-Controlled Trial of Ketamine for Methamphetamine Use Disorder (KMD)
Record updated
27 October 2026